
New WCLC insights show how EGFR and KRAS G12C biomarkers shape lung cancer biology, resistance, prognosis, and smarter testing for personalized care.
Two medical oncologists recording at the 2026 World Conference on Lung Cancer (WCLC) in Seoul use new evidence as a way into 2 biomarkers in non-small cell lung cancer (NSCLC). The program covers what EGFR and KRAS G12C results tell a clinician beyond treatment selection, the EGFR result at progression and the updated HARMONi overall survival analysis, AMIGO-1 and COPERNICUS data, EGFR and central nervous system disease, KRAS G12C in practice and neoadjuvant NAUTIKA1 data, broad molecular profiling from diagnosis, and closing clinical pearls.

New WCLC insights show how EGFR and KRAS G12C biomarkers shape lung cancer biology, resistance, prognosis, and smarter testing for personalized care.

After EGFR TKI progression, clinicians reassess biopsy and NGS for resistance drivers and weigh emerging survival data for ivonesmab plus chemotherapy.

Experts weigh new lung cancer trial strategies, balancing stronger EGFR regimens against safer delivery, plus advances in leptomeningeal diagnosis and KRAS G12C timing.

New lung cancer studies weigh EGFR regimen intensification against improved supportive care, while experts spotlight leptomeningeal testing advances and evolving KRAS G12C targeting.